Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

Pre-surgical neoadjuvant oncolytic virotherapy confers protection against rechallenge in a murine model of breast cancer.

Martin NT, Roy DG, Workenhe ST, van den Wollenberg DJM, Hoeben RC, Mossman KL, Bell JC, Bourgeois-Daigneault MC.

Sci Rep. 2019 Feb 12;9(1):1865. doi: 10.1038/s41598-018-38385-7.

2.

Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis.

Zakaria C, Sean P, Hoang HD, Leroux LP, Watson M, Workenhe ST, Hearnden J, Pearl D, Truong VT, Robichaud N, Yanagiya A, Tahmasebi S, Jafarnejad SM, Jia JJ, Pelin A, Diallo JS, Le Boeuf F, Bell JC, Mossman KL, Graber TE, Jaramillo M, Sonenberg N, Alain T.

PLoS Pathog. 2018 Aug 23;14(8):e1007264. doi: 10.1371/journal.ppat.1007264. eCollection 2018 Aug.

3.

IL-15 and IFN-γ signal through the ERK pathway to inhibit HCV replication, independent of type I IFN signaling.

Vahedi F, Lee AJ, Collins SE, Chew MV, Lusty E, Chen B, Dubey A, Richards CD, Feld JJ, Russell RS, Mossman KL, Ashkar AA.

Cytokine. 2018 Jun 13. pii: S1043-4666(18)30254-0. doi: 10.1016/j.cyto.2018.06.006. [Epub ahead of print]

PMID:
29908921
4.

Direct binding and internalization of diverse extracellular nucleic acid species through the collagenous domain of class A scavenger receptors.

Baid K, Nellimarla S, Huynh A, Boulton S, Guarné A, Melacini G, Collins SE, Mossman KL.

Immunol Cell Biol. 2018 Oct;96(9):922-934. doi: 10.1111/imcb.12052. Epub 2018 Apr 26.

PMID:
29617041
5.

Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies.

van Vloten JP, Workenhe ST, Wootton SK, Mossman KL, Bridle BW.

J Immunol. 2018 Jan 15;200(2):450-458. doi: 10.4049/jimmunol.1701021. Review.

6.

Interferon-Dependent Induction of Clr-b during Mouse Cytomegalovirus Infection Protects Bystander Cells from Natural Killer Cells via NKR-P1B-Mediated Inhibition.

Kirkham CL, Aguilar OA, Yu T, Tanaka M, Mesci A, Chu KL, Fine JH, Mossman KL, Bremner R, Allan DSJ, Carlyle JR.

J Innate Immun. 2017;9(4):343-358. doi: 10.1159/000454926. Epub 2017 Mar 14.

7.

Inflammatory monocytes require type I interferon receptor signaling to activate NK cells via IL-18 during a mucosal viral infection.

Lee AJ, Chen B, Chew MV, Barra NG, Shenouda MM, Nham T, van Rooijen N, Jordana M, Mossman KL, Schreiber RD, Mack M, Ashkar AA.

J Exp Med. 2017 Apr 3;214(4):1153-1167. doi: 10.1084/jem.20160880. Epub 2017 Mar 6.

8.

Viral Evasion Strategies in Type I IFN Signaling - A Summary of Recent Developments.

Schulz KS, Mossman KL.

Front Immunol. 2016 Nov 11;7:498. eCollection 2016. Review.

9.

Membrane Perturbation-Associated Ca2+ Signaling and Incoming Genome Sensing Are Required for the Host Response to Low-Level Enveloped Virus Particle Entry.

Hare DN, Collins SE, Mukherjee S, Loo YM, Gale M Jr, Janssen LJ, Mossman KL.

J Virol. 2015 Dec 30;90(6):3018-27. doi: 10.1128/JVI.02642-15.

10.

Type I interferon restricts type 2 immunopathology through the regulation of group 2 innate lymphoid cells.

Duerr CU, McCarthy CD, Mindt BC, Rubio M, Meli AP, Pothlichet J, Eva MM, Gauchat JF, Qureshi ST, Mazer BD, Mossman KL, Malo D, Gamero AM, Vidal SM, King IL, Sarfati M, Fritz JH.

Nat Immunol. 2016 Jan;17(1):65-75. doi: 10.1038/ni.3308. Epub 2015 Nov 23.

PMID:
26595887
11.

A Lymphotoxin/Type I IFN Axis Programs CD8+ T Cells To Infiltrate a Self-Tissue and Propagate Immunopathology.

Ng D, Maître B, Cummings D, Lin A, Ward LA, Rahbar R, Mossman KL, Ohashi PS, Gommerman JL.

J Immunol. 2015 Nov 15;195(10):4650-9. doi: 10.4049/jimmunol.1501053. Epub 2015 Oct 12.

12.

Class A Scavenger Receptor-Mediated Double-Stranded RNA Internalization Is Independent of Innate Antiviral Signaling and Does Not Require Phosphatidylinositol 3-Kinase Activity.

Nellimarla S, Baid K, Loo YM, Gale M Jr, Bowdish DM, Mossman KL.

J Immunol. 2015 Oct 15;195(8):3858-65. doi: 10.4049/jimmunol.1501028. Epub 2015 Sep 11.

13.

Genome-wide lentiviral shRNA screen identifies serine/arginine-rich splicing factor 2 as a determinant of oncolytic virus activity in breast cancer cells.

Workenhe ST, Ketela T, Moffat J, Cuddington BP, Mossman KL.

Oncogene. 2016 May 12;35(19):2465-74. doi: 10.1038/onc.2015.303. Epub 2015 Aug 10.

PMID:
26257065
14.

Widely Used Herpes Simplex Virus 1 ICP0 Deletion Mutant Strain dl1403 and Its Derivative Viruses Do Not Express Glycoprotein C Due to a Secondary Mutation in the gC Gene.

Cunha CW, Taylor KE, Pritchard SM, Delboy MG, Komala Sari T, Aguilar HC, Mossman KL, Nicola AV.

PLoS One. 2015 Jul 17;10(7):e0131129. doi: 10.1371/journal.pone.0131129. eCollection 2015.

15.

Cellular Protein WDR11 Interacts with Specific Herpes Simplex Virus Proteins at the trans-Golgi Network To Promote Virus Replication.

Taylor KE, Mossman KL.

J Virol. 2015 Oct;89(19):9841-52. doi: 10.1128/JVI.01705-15. Epub 2015 Jul 15.

16.

Consensus guidelines for the detection of immunogenic cell death.

Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fučíková J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 13;3(9):e955691. eCollection 2014 Oct. Review.

17.

Oncolytic bovine herpesvirus type 1 as a broad spectrum cancer therapeutic.

Cuddington BP, Mossman KL.

Curr Opin Virol. 2015 Aug;13:11-6. doi: 10.1016/j.coviro.2015.03.010. Epub 2015 Apr 2. Review.

PMID:
25846987
18.

The role of oncolytic virus immunotherapies to subvert cancer immune evasion.

Workenhe ST, Verschoor ML, Mossman KL.

Future Oncol. 2015;11(4):675-89. doi: 10.2217/fon.14.254. Review.

PMID:
25686121
19.

HSV cheats the executioner.

Mossman KL, Weller SK.

Cell Host Microbe. 2015 Feb 11;17(2):148-51. doi: 10.1016/j.chom.2015.01.013.

20.

Enhanced efficacy with azacytidine and oncolytic BHV-1 in a tolerized cotton rat model of breast adenocarcinoma.

Cuddington BP, Verschoor M, Ashkar A, Mossman KL.

Mol Ther Oncolytics. 2015 Mar 25;2:15004. doi: 10.1038/mto.2015.4. eCollection 2015.

21.

Danger, diversity and priming in innate antiviral immunity.

Collins SE, Mossman KL.

Cytokine Growth Factor Rev. 2014 Oct;25(5):525-31. doi: 10.1016/j.cytogfr.2014.07.002. Epub 2014 Jul 11. Review.

PMID:
25081316
22.

Type-I interferon signaling through ISGF3 complex is required for sustained Rip3 activation and necroptosis in macrophages.

McComb S, Cessford E, Alturki NA, Joseph J, Shutinoski B, Startek JB, Gamero AM, Mossman KL, Sad S.

Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):E3206-13. doi: 10.1073/pnas.1407068111. Epub 2014 Jul 21.

23.

Extracellular dsRNA: its function and mechanism of cellular uptake.

Nellimarla S, Mossman KL.

J Interferon Cytokine Res. 2014 Jun;34(6):419-26. doi: 10.1089/jir.2014.0002. Review.

PMID:
24905198
24.

Cancer complexity and radiation protection.

Mossman KL.

Health Phys. 2014 Jul;107(1):73-9. doi: 10.1097/HP.0000000000000054.

PMID:
24849905
25.
26.

Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy.

Workenhe ST, Pol JG, Lichty BD, Cummings DT, Mossman KL.

Cancer Immunol Res. 2013 Nov;1(5):309-19. doi: 10.1158/2326-6066.CIR-13-0059-T. Epub 2013 Aug 19.

27.

Permissiveness of human cancer cells to oncolytic bovine herpesvirus 1 is mediated in part by KRAS activity.

Cuddington BP, Mossman KL.

J Virol. 2014 Jun;88(12):6885-95. doi: 10.1128/JVI.00849-14. Epub 2014 Apr 2.

28.

Rewiring cancer cell death to enhance oncolytic viro-immunotherapy.

Workenhe ST, Mossman KL.

Oncoimmunology. 2013 Dec 1;2(12):e27138. Epub 2013 Dec 9.

29.

Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.

Workenhe ST, Simmons G, Pol JG, Lichty BD, Halford WP, Mossman KL.

Mol Ther. 2014 Jan;22(1):123-31. doi: 10.1038/mt.2013.238. Epub 2013 Oct 9.

30.

Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies.

Workenhe ST, Mossman KL.

Mol Ther. 2014 Feb;22(2):251-256. doi: 10.1038/mt.2013.220. Epub 2013 Oct 19. Review.

31.

HIV-1 gp120 induces TLR2- and TLR4-mediated innate immune activation in human female genital epithelium.

Nazli A, Kafka JK, Ferreira VH, Anipindi V, Mueller K, Osborne BJ, Dizzell S, Chauvin S, Mian MF, Ouellet M, Tremblay MJ, Mossman KL, Ashkar AA, Kovacs C, Bowdish DM, Snider DP, Kaul R, Kaushic C.

J Immunol. 2013 Oct 15;191(8):4246-58. doi: 10.4049/jimmunol.1301482. Epub 2013 Sep 16.

32.

Novel paradigms of innate immune sensing of viral infections.

Hare D, Mossman KL.

Cytokine. 2013 Sep;63(3):219-24. doi: 10.1016/j.cyto.2013.06.001. Epub 2013 Jun 22. Review.

PMID:
23800788
33.
34.

Oncolytic bovine herpesvirus type 1 infects and kills breast tumor cells and breast cancer-initiating cells irrespective of tumor subtype.

Cuddington BP, Dyer AL, Workenhe ST, Mossman KL.

Cancer Gene Ther. 2013 May;20(5):282-9. doi: 10.1038/cgt.2013.18. Epub 2013 Apr 26.

PMID:
23618948
35.

The herpes simplex virus 1-encoded envelope glycoprotein B activates NF-κB through the Toll-like receptor 2 and MyD88/TRAF6-dependent signaling pathway.

Cai M, Li M, Wang K, Wang S, Lu Q, Yan J, Mossman KL, Lin R, Zheng C.

PLoS One. 2013;8(1):e54586. doi: 10.1371/journal.pone.0054586. Epub 2013 Jan 28.

36.

MARCO is required for TLR2- and Nod2-mediated responses to Streptococcus pneumoniae and clearance of pneumococcal colonization in the murine nasopharynx.

Dorrington MG, Roche AM, Chauvin SE, Tu Z, Mossman KL, Weiser JN, Bowdish DM.

J Immunol. 2013 Jan 1;190(1):250-8. doi: 10.4049/jimmunol.1202113. Epub 2012 Nov 28.

37.

Recent advances in understanding viral evasion of type I interferon.

Taylor KE, Mossman KL.

Immunology. 2013 Mar;138(3):190-7. doi: 10.1111/imm.12038. Review.

38.

The LNT Debate in Radiation Protection: Science vs. Policy.

Mossman KL.

Dose Response. 2012;10(2):190-202. doi: 10.2203/dose-response.11-017.Mossman. Epub 2011 Jun 15.

39.

Adenovirus evasion of interferon-mediated innate immunity by direct antagonism of a cellular histone posttranslational modification.

Fonseca GJ, Thillainadesan G, Yousef AF, Ablack JN, Mossman KL, Torchia J, Mymryk JS.

Cell Host Microbe. 2012 Jun 14;11(6):597-606. doi: 10.1016/j.chom.2012.05.005.

40.

The nitric oxide pathway provides innate antiviral protection in conjunction with the type I interferon pathway in fibroblasts.

Mehta DR, Ashkar AA, Mossman KL.

PLoS One. 2012;7(2):e31688. doi: 10.1371/journal.pone.0031688. Epub 2012 Feb 21.

41.

Herpes simplex virus 1 tegument protein US11 downmodulates the RLR signaling pathway via direct interaction with RIG-I and MDA-5.

Xing J, Wang S, Lin R, Mossman KL, Zheng C.

J Virol. 2012 Apr;86(7):3528-40. doi: 10.1128/JVI.06713-11. Epub 2012 Feb 1.

42.

Varicella-zoster virus immediate-early protein ORF61 abrogates the IRF3-mediated innate immune response through degradation of activated IRF3.

Zhu H, Zheng C, Xing J, Wang S, Li S, Lin R, Mossman KL.

J Virol. 2011 Nov;85(21):11079-89. doi: 10.1128/JVI.05098-11. Epub 2011 Aug 10.

43.

Membrane perturbation elicits an IRF3-dependent, interferon-independent antiviral response.

Noyce RS, Taylor K, Ciechonska M, Collins SE, Duncan R, Mossman KL.

J Virol. 2011 Oct;85(20):10926-31. doi: 10.1128/JVI.00862-11. Epub 2011 Aug 3.

44.

A critical role for IL-15 in TLR-mediated innate antiviral immunity against genital HSV-2 infection.

Thatte A, DeWitte-Orr SJ, Lichty B, Mossman KL, Ashkar AA.

Immunol Cell Biol. 2011 Aug;89(6):663-9. doi: 10.1038/icb.2011.7. Epub 2011 Feb 22.

PMID:
21339766
45.

IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells.

Boudreau JE, Stephenson KB, Wang F, Ashkar AA, Mossman KL, Lenz LL, Rosenthal KL, Bramson JL, Lichty BD, Wan Y.

Cancer Res. 2011 Apr 1;71(7):2497-506. doi: 10.1158/0008-5472.CAN-10-3025. Epub 2011 Feb 9.

46.

Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy.

Sobol PT, Boudreau JE, Stephenson K, Wan Y, Lichty BD, Mossman KL.

Mol Ther. 2011 Feb;19(2):335-44. doi: 10.1038/mt.2010.264. Epub 2010 Nov 30.

47.

The dose from Compton backscatter screening.

Rez P, Metzger RL, Mossman KL.

Radiat Prot Dosimetry. 2011 Apr;145(1):75-81. doi: 10.1093/rpd/ncq358. Epub 2010 Nov 9.

PMID:
21068018
48.

Treating viral exacerbations of chronic obstructive pulmonary disease: insights from a mouse model of cigarette smoke and H1N1 influenza infection.

Bauer CM, Zavitz CC, Botelho FM, Lambert KN, Brown EG, Mossman KL, Taylor JD, Stämpfli MR.

PLoS One. 2010 Oct 12;5(10):e13251. doi: 10.1371/journal.pone.0013251.

49.

Replication of subgenomic hepatitis C virus replicons in mouse fibroblasts is facilitated by deletion of interferon regulatory factor 3 and expression of liver-specific microRNA 122.

Lin LT, Noyce RS, Pham TN, Wilson JA, Sisson GR, Michalak TI, Mossman KL, Richardson CD.

J Virol. 2010 Sep;84(18):9170-80. doi: 10.1128/JVI.00559-10. Epub 2010 Jun 30.

50.

Recognition of virus infection and innate host responses to viral gene therapy vectors.

Shayakhmetov DM, Di Paolo NC, Mossman KL.

Mol Ther. 2010 Aug;18(8):1422-9. doi: 10.1038/mt.2010.124. Epub 2010 Jun 15. Review.

Supplemental Content

Loading ...
Support Center